CVS Health Form 4 shows director stock retainer grant
Rhea-AI Filing Summary
CVS Health Corp reported an insider equity transaction by a company director on a Form 4. On 11/20/2025, the director acquired 1,775 shares of CVS Health common stock, labeled as an acquisition, at a price of $76.04 per share. The filing explains that these shares were issued as payment of a semi-annual retainer at the market price under the company’s 2017 Incentive Compensation Plan, meaning they represent stock-based compensation rather than an open-market purchase. Following this transaction, the director directly owns 127,772 shares of CVS Health common stock.
Positive
- None.
Negative
- None.
FAQ
What insider transaction did CVS (CVS) report in this Form 4?
The Form 4 reports that a director of CVS Health Corp acquired 1,775 shares of common stock on 11/20/2025 as part of their compensation.
At what price were the CVS (CVS) shares valued in the director’s Form 4 grant?
The 1,775 CVS Health common shares were issued at a market price of $76.04 per share as noted in the Form 4.
How many CVS (CVS) shares does the director own after this Form 4 transaction?
After the reported transaction, the director directly owns 127,772 shares of CVS Health common stock.
What is the purpose of the CVS (CVS) share grant reported in the Form 4?
The 1,775 shares were issued in payment of a semi-annual retainer at the market price under CVS Health’s 2017 Incentive Compensation Plan.
Is the CVS (CVS) Form 4 transaction a purchase on the open market?
No. The Form 4 states the common stock was issued in payment of a semi-annual retainer, indicating it is stock-based compensation rather than an open-market buy.
What role does the reporting person have at CVS (CVS)?
The reporting person is identified as a Director of CVS Health Corp, filing individually as one reporting person on the Form 4.